Sandoz semaglutide: what UK patients need to know

What is Sandoz semaglutide, and does it exist in the UK?

Sandoz is one of the world's largest manufacturers of generic and biosimilar medicines. In recent years the company announced development of a biosimilar semaglutide product, attracting considerable interest from people watching the weight-management market. A biosimilar is a medicine that closely matches an approved biological medicine once the originator's patent protection expires or is challenged.

In the UK, however, no Sandoz semaglutide product has received MHRA approval for weight management. The regulator that licenses medicines in this country is the MHRA, and the only semaglutide currently authorised here for weight loss is Wegovy, produced by Novo Nordisk. You can read a full overview of how semaglutide works and what the licensed treatment involves on our semaglutide information page.

That may change. Generic and biosimilar markets evolve, and regulators do receive and assess new applications. But for now, if you have read about Sandoz semaglutide on a forum or a social-media post and wondered whether it is something you can obtain in the UK, the honest answer is: not through a legitimate, regulated route. Any seller offering unlicensed medicines deserves serious caution, and the MHRA has consistently warned the public about buying injectable weight-loss medicines from unverified online sources.

The practical upshot for UK patients is straightforward. Licensed semaglutide treatment means Wegovy. That is where the clinical evidence, the prescriber training, and the regulatory oversight sit.

How does licensed semaglutide for weight loss actually work?

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 is a hormone released by the gut after eating; it signals fullness to the brain, slows the rate at which the stomach empties, and plays a role in regulating blood sugar. Semaglutide mimics that signal, which is why many people taking it find their appetite noticeably reduced and feel satisfied with smaller amounts of food.

The Wegovy injection is given once a week, starting at a low dose to allow the body to adjust, then stepped up by a prescriber over several months toward the maintenance dose. The titration schedule exists for good reason, starting too fast tends to increase the chance of gastrointestinal side effects such as nausea, vomiting, or loose stools, which are the most commonly reported effects. For most people these settle as the body adapts, but they are worth knowing about before starting.

The STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose alongside lifestyle changes, and you can find the detail behind that starting dose in our guide to semaglutide 1 mg dosing. A higher 7.2 mg dose, approved by the MHRA in early 2026, showed around 20.7% average weight loss in trials, and the steps that lead toward it are covered in our semaglutide 2 mg dosing guide. Results vary between individuals, and clinical trial participants follow closely supervised conditions, no figure should be taken as a personal guarantee.

There is also now an oral version. The MHRA approved Wegovy tablets in June 2026, making it the first oral GLP-1 medicine licensed for weight management in the UK. If the idea of a daily tablet rather than a weekly injection appeals to you, our Wegovy page covers both forms in detail.

Who can access licensed semaglutide treatment in the UK?

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, raised cholesterol, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. These are the licence parameters; a prescriber also considers your full medical history, any medicines you take, and any conditions that might make treatment unsuitable.

On the NHS, access to Wegovy sits within specialist weight management services, and waiting lists can be long. NICE's appraisal of semaglutide for weight management (TA875) sets out the clinical criteria and conditions of use, including a maximum two-year treatment period under NHS commissioning.

Private treatment through a regulated online pharmacy is the alternative for people who do not meet NHS criteria yet, or who would prefer not to wait. The cost of private treatment is a fair question, and our Wegovy pricing page sets out what to expect honestly. If you are weighing up your options more broadly, the weight-loss treatments overview is a helpful starting point.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive, and it is not licensed for under-18s. A prescriber will go through all of this with you at assessment.

What should I do if I have seen Sandoz semaglutide advertised for sale?

This is a question worth pausing on. The MHRA has issued repeated public warnings about fake and unlicensed injectable weight-loss medicines being sold through social media, unofficial websites, and even some gym networks. Some counterfeit pens seized in the UK have been found to contain insulin rather than the medicine they claimed to carry, a potentially life-threatening substitution.

A legitimate prescription medicine in the UK travels through the licensed supply chain and is dispensed by a pharmacy you can verify on the GPhC register. If a product is being offered without a clinical assessment, at prices dramatically below the market, or by a seller you cannot independently verify, those are serious red flags, not bargains. Our semaglutide 3 mg information page is a good example of the kind of transparent, clinically reviewed dosing guidance you should expect from any regulated provider.

If you want to explore whether licensed semaglutide treatment is appropriate for you, the right route is a consultation with a qualified prescriber. Our clinical team, led by our independent prescriber, reviews every consultation personally. If you have questions before starting, the FAQs or our support team are there for you. Suspected unlicensed sellers can be reported to the MHRA via the Yellow Card scheme.

One practical note: if you are thinking about starting treatment and your week runs to a rhythm (payday, a bank holiday, the school run) it is worth knowing that orders placed by noon on any working day, once approved, are dispatched the same afternoon. There is no pressure to rush a decision, but the process is faster than many people expect once you are ready.

If you would like a clinician to review your situation, you can check your eligibility with a free consultation at any point.